Guideline Recommendations for Initial Management of Newly Diagnosed Hypertension in Adults Without Comorbidities

Initial Assessment and Diagnosis

Confirm the diagnosis of hypertension (office BP ≥ 140/90 mmHg) with out‑of‑office measurements (home or ambulatory monitoring) before starting treatment, to avoid white‑coat hypertension. European Society of Cardiology (ESC) – Class I, Level A 1, 2

Aim for a systolic blood pressure of 120–129 mmHg in most adults, provided the regimen is well tolerated. ESC – Class I, Level A 1, 3, 4
If the intensive target is poorly tolerated, apply the “as low as reasonably achievable” (ALARA) principle and maintain BP < 130/80 mmHg at minimum. ESC – Class I, Level B 1, 4
The 2025 American Heart Association/American College of Cardiology (AHA/ACC) guideline aligns with the ESC recommendation for this intensive target. AHA/ACC – Class I, Level A 5, 1

Begin treatment immediately with a two‑drug combination (preferably a single‑pill formulation) rather than monotherapy. ESC – Strong recommendation (Class I, Level A) 1, 3, 2
Preferred initial combinations:
- RAS blocker (ACE inhibitor or ARB) + dihydropyridine calcium‑channel blocker (CCB)
- RAS blocker (ACE inhibitor or ARB) + thiazide‑like diuretic (chlorthalidone or indapamide)
  ESC – Strong recommendation (Class I, Level A) 1, 3, 2
The four drug classes—ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide‑like diuretics—have the greatest evidence for BP reduction and cardiovascular event prevention. ESC – Class I, Level A 1, 3
Never combine two RAS blockers (e.g., ACE inhibitor + ARB). ESC – Class III, Level A (harm) 1, 3, 2

Initiate lifestyle modifications simultaneously with pharmacologic therapy; do not delay medication while trialing lifestyle changes alone. ESC – Class I, Level A 1, 3, 2
Core interventions (all ESC recommendations, Class I, Level B):
- Sodium restriction – reduce dietary sodium intake. 1, 3
- Limit free sugars to ≤ 10 % of total energy, especially avoiding sugar‑sweetened beverages. 1, 3
- Alcohol moderation – avoid or minimize consumption. 1, 3
- Tobacco cessation – provide referral to cessation programs. 1, 3
- Weight management for overweight or obese individuals. 1, 3

If BP remains uncontrolled on the initial two‑drug combo, escalate to a three‑drug single‑pill combination: RAS blocker + dihydropyridine CCB + thiazide‑like diuretic. ESC – Class I, Level A 1, 3, 2, 4
If uncontrolled on three drugs, add spironolactone (mineralocorticoid receptor antagonist). ESC – Class I, Level B 2
If spironolactone is not tolerated or contraindicated, consider eplerenone, a beta‑blocker (only if no compelling indication), an alpha‑blocker, or a centrally acting agent. ESC – Class IIa, Level B 2

Schedule frequent follow‑up visits every 1–3 months until BP is controlled, aiming to achieve target within 3 months of therapy initiation. ESC – Class I, Level A 2

Perform urinalysis at diagnosis to uncover occult kidney disease. ESC – Class I, Level B 4

Advise patients to take antihypertensive medications at the most convenient time of day to foster habit formation; consistency is more important than exact timing. ESC – Class I, Level B 1, 3

Continue BP‑lowering therapy lifelong, even beyond age 85, if well tolerated. ESC – Class I, Level A 1, 3, 4
If lifestyle changes achieve sufficient BP control, down‑titrate or discontinue drugs cautiously with close monitoring. ESC – Class IIa, Level B 2

Do not delay pharmacologic therapy to trial lifestyle changes alone in confirmed hypertension (≥ 140/90 mmHg). ESC – Class I, Level A 1, 3, 2
Do not start with monotherapy in most patients with BP ≥ 140/90 mmHg. ESC – Class I, Level A 1, 3, 2
Do not use beta‑blockers as first‑line unless there is a compelling indication (post‑MI, heart failure, angina, rate control). ESC – Class III, Level B 1, 3
Avoid combining ACE inhibitor + ARB due to lack of benefit and increased harm. ESC – Class III, Level A 1, 3, 2
Do not accept suboptimal BP control; systematically intensify therapy if target is not reached within 3 months. ESC – Class I, Level A 2

Patients should sit quietly in a chair with feet flat on the floor and back supported for more than 5 minutes before measurement. 6
At least 30 minutes before the reading, patients must avoid caffeine, vigorous exercise, and smoking. 6
The patient’s bladder should be emptied prior to measurement. 6
Neither the patient nor the observer should speak during the rest period or the measurement itself. 6
The arm must be supported at heart level (mid‑sternum). 6
Use a cuff that covers ≈ 80 % of the upper‑arm circumference to ensure accurate sizing. 6
Only blood‑pressure devices that have been validated and are periodically calibrated should be employed. 6
Measurements taken while the patient is seated or lying on an examination table do not satisfy proper diagnostic criteria. 6

An office blood pressure ≥ 140/90 mmHg defines hypertension according to traditional guideline thresholds. 6

Guidelines advise that blood‑pressure readings be averaged over ≥ 2 separate occasions before a definitive diagnosis is made. 6

Step 1: Perform an initial office measurement using the standardized technique; a reading ≥ 140/90 mmHg triggers further evaluation. 6
Step 2: Confirm the elevated office reading with out‑of‑office measurements (home or ambulatory monitoring) before initiating treatment. 6
Step 3: If office and out‑of‑office measurements are discordant, obtain 24‑hour ambulatory blood‑pressure monitoring to establish a definitive diagnosis. 6

All statements are derived from the 2018 Circulation guideline.